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Background
Controlled human malaria infection (CHMI) studies,
where healthy volunteers are infected with Plasmodium
falciparum have become a vital tool to accelerate vaccine
and drug development. As CHMI trials are carried out in
a controlled environment, they allow unprecedented,
detailed evaluation of parasite growth dynamics and
immunological responses to infection. Though commonly
performed in malaria-naïve populations, CHMI trials
have rarely been performed in malaria endemic regions,
despite the advantages of early testing of candidate anti-
malaria vaccines and drugs in populations where malaria
is endemic. To date, modern CHMI studies have not
been used to investigate mechanisms of naturally
acquired immunity (NAI) to P. falciparum infection.
Materials and methods
We conducted an open label, randomized CHMI pilot
study using aseptic, cryopreserved P. falciparum sporo-
zoites (PfSPZ Challenge) administered intramuscularly
to evaluate safety, infectivity and parasite growth
dynamics in healthy Kenyan adults (n = 28). We
included adults with varying degrees of prior exposure
to malaria in order to allow an evaluation of the effect
of NAI on parasite growth dynamics post CHMI.
Results
All participants developed blood-stage infection, with a
similar safety profile to that observed in northern CHMI
centres. One volunteer remained asymptomatic and
blood-film negative until day 21 post injection of PfSPZ
Challenge, despite developing confirmed blood-stage
infection by quantitative polymerase chain reaction
(qPCR). This volunteer had a notably reduced parasite
multiplication rate (1.3) in comparison to the other 27
volunteers (median 11.1). A significant correlation was
seen between parasite multiplication rate (PMR) and
anti-schizont ELISA OD at screening (P = 0.044).
Conclusions
Our study has shown that the PfSPZ Challenge is safe
and infectious in malaria endemic populations and
could be used to aid early assessment of the efficacy of
candidate malaria vaccines and drugs in African popula-
tions. Whilst our findings are limited by sample size,
our pilot study proves that NAI can impact on PMR
post-CHMI in a detectable fashion. Our findings suggest
the CHMI sporozoite model could allow identification
of a heterogeneous group of participants with varying
degrees of NAI for whom the relationship between PMR
and candidate assays of blood-stage immunity can be
examined to try to gain greater understanding of the
mechanisms of NAI to P. falciparum malaria.
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